Comparison
Omega-3 (DHA/EPA) vs CBD (Cannabidiol)
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
CBD (Cannabidiol)
Non-psychoactive cannabinoid from hemp. Anxiolytic, anti-seizure, anti-inflammatory. The supplement market has grown explosively despite mixed evidence base.
| Field | Omega-3 (DHA/EPA) | CBD (Cannabidiol) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 25–600mg |
| Half-life | 24h | – |
| Onset | – | – |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 5200 | 6800 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and CBD (Cannabidiol) are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. CBD (Cannabidiol) Non-psychoactive cannabinoid from hemp.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) has a weaker evidence base than CBD (Cannabidiol) (evidence B, safety 4/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose CBD (Cannabidiol) if
CBD (Cannabidiol) is the better fit when your goal aligns with its mechanism (Modulates the endocannabinoid system through indirect mechanisms, CBD doesn't bind CB1 or CB2 receptors directly like THC does) and the dose range (25–600mg) suits your protocol. Half-life is –h.